Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.8 USD | -3.13% | -0.17% | +196.35% |
Financials (USD)
Sales 2024 * | 2.14M | Sales 2025 * | - | Capitalization | 715M |
---|---|---|---|---|---|
Net income 2024 * | -66M | Net income 2025 * | -93M | EV / Sales 2024 * | 209 x |
Net cash position 2024 * | 267M | Net cash position 2025 * | 320M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-9.87
x | P/E ratio 2025 * |
-8.05
x | Employees | 50 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.5% |
Latest transcript on Longboard Pharmaceuticals, Inc.
1 day | +1.72% | ||
1 week | +0.93% | ||
Current month | -2.60% | ||
1 month | -14.01% | ||
3 months | -10.12% | ||
6 months | +359.50% | ||
Current year | +204.81% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Lind
CEO | Chief Executive Officer | 47 | 20-01-02 |
Brandi Roberts
DFI | Director of Finance/CFO | 50 | 20-12-31 |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Sekhri
CHM | Chairman | 66 | 20-11-30 |
Director/Board Member | 68 | 20-11-30 | |
Vincent Aurentz
BRD | Director/Board Member | 56 | 20-01-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.41% | 4 M€ | -5.15% | - | |
0.00% | 34 M€ | +4.32% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-06 | 17.93 | -2.45% | 89 920 |
24-06-05 | 18.38 | +1.72% | 184,079 |
24-06-04 | 18.07 | -4.54% | 201,599 |
24-06-03 | 18.93 | +0.32% | 262,585 |
24-05-31 | 18.87 | +5.42% | 626,829 |
Delayed Quote Nasdaq, June 05, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+204.81% | 715M | |
+18.72% | 125B | |
+14.53% | 109B | |
-2.88% | 24.74B | |
+2.18% | 22.67B | |
-10.09% | 18.14B | |
-41.04% | 16.67B | |
-11.83% | 16.64B | |
+1.46% | 13.45B | |
+24.22% | 11.32B |
- Stock Market
- Equities
- LBPH Stock